Blackstone says real estate executive Wesley LePatner was among those killed in NYC shooting
LePatner, a mother and wife, was the $1.2 trillion firm's global head of core+ real estate and CEO of Blackstone Real Estate Income Trust, an evergreen real estate fund. Her death has left staff at the New York-based asset manager "heartbroken," the statement said.
"Words cannot express the devastation we feel. Wesley was a beloved member of the Blackstone family and will be sorely missed. She was brilliant, passionate, warm, generous, and deeply respected within our firm and beyond. She embodied the best of Blackstone," the statement continued.
LePatner, a Yale graduate and trustee of New York's Met Museum, was an executive at Goldman Sachs before joining Blackstone in 2014.
She told Business Insider in 2022 that her unit was, "for all intents and purposes, a startup."
"I faced all the challenges one could imagine when building a multibillion-dollar business — from hiring to ensuring standards remain high, moving quickly to keep up with growth, and staying ahead of market swings and growing pains," she said.
She also served on the board for the UJA-Federation of New York, which honored her at its Wall Street dinner in 2023. Blackstone's President Jon Gray presented her with a leadership award and lauded her ascent in finance and her support of women on Wall Street, according to a press release.
LePatner is one of four victims who lost their lives to the gunman, who has been identified by the police as Shane Tamura. The gunman died of an apparent self-inflicted gunshot wound in the building.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Bristol-Myers Squibb (NYSE:BMY) Reports Strong Q2, Full-Year Sales Guidance is Optimistic
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q2 CY2025, but sales were flat year on year at $12.27 billion. The company's full-year revenue guidance of $47 billion at the midpoint came in 1.6% above analysts' estimates. Its non-GAAP profit of $1.46 per share was 32.6% above analysts' consensus estimates. Is now the time to buy Bristol-Myers Squibb? Find out in our full research report. Bristol-Myers Squibb (BMY) Q2 CY2025 Highlights: Revenue: $12.27 billion vs analyst estimates of $11.38 billion (flat year on year, 7.8% beat) Adjusted EPS: $1.46 vs analyst estimates of $1.10 (32.6% beat) The company lifted its revenue guidance for the full year to $47 billion at the midpoint from $46.3 billion, a 1.5% increase Management lowered its full-year Adjusted EPS guidance to $6.50 at the midpoint, a 5.1% decrease Operating Margin: 14.5%, up from 12.8% in the same quarter last year Market Capitalization: $93.57 billion Company Overview With roots dating back to 1887 and a transformative merger in 1989 that gave the company its current name, Bristol-Myers Squibb (NYSE:BMY) discovers, develops, and markets prescription medications for serious diseases including cancer, blood disorders, immunological conditions, and cardiovascular diseases. Revenue Growth Examining a company's long-term performance can provide clues about its quality. Any business can have short-term success, but a top-tier one grows for years. Regrettably, Bristol-Myers Squibb's sales grew at a mediocre 6.5% compounded annual growth rate over the last five years. This was below our standard for the healthcare sector and is a tough starting point for our analysis. We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Bristol-Myers Squibb's recent performance shows its demand has slowed as its annualized revenue growth of 2.7% over the last two years was below its five-year trend. We can better understand the company's revenue dynamics by analyzing its most important segment, Growth Portfolio. Over the last two years, Bristol-Myers Squibb's Growth Portfolio revenue averaged 17.4% year-on-year growth. This segment has outperformed its total sales during the same period, lifting the company's performance. This quarter, Bristol-Myers Squibb's $12.27 billion of revenue was flat year on year but beat Wall Street's estimates by 7.8%. Looking ahead, sell-side analysts expect revenue to decline by 5.8% over the next 12 months, a deceleration versus the last two years. This projection is underwhelming and suggests its products and services will face some demand challenges. Software is eating the world and there is virtually no industry left that has been untouched by it. That drives increasing demand for tools helping software developers do their jobs, whether it be monitoring critical cloud infrastructure, integrating audio and video functionality, or ensuring smooth content streaming. Click here to access a free report on our 3 favorite stocks to play this generational megatrend. Operating Margin Operating margin is one of the best measures of profitability because it tells us how much money a company takes home after subtracting all core expenses, like marketing and R&D. Bristol-Myers Squibb was profitable over the last five years but held back by its large cost base. Its average operating margin of 9.1% was weak for a healthcare business. On the plus side, Bristol-Myers Squibb's operating margin rose by 6.9 percentage points over the last five years, as its sales growth gave it operating leverage. Zooming into its more recent performance, however, we can see the company's margin has decreased by 1.6 percentage points on a two-year basis. If Bristol-Myers Squibb wants to pass our bar, it must prove it can expand its profitability consistently. In Q2, Bristol-Myers Squibb generated an operating margin profit margin of 14.5%, up 1.7 percentage points year on year. This increase was a welcome development and shows it was more efficient. Earnings Per Share We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company's growth is profitable. Bristol-Myers Squibb's EPS grew at an unimpressive 3.2% compounded annual growth rate over the last five years, lower than its 6.5% annualized revenue growth. We can see the difference stemmed from higher interest expenses or taxes as the company actually improved its operating margin and repurchased its shares during this time. In Q2, Bristol-Myers Squibb reported adjusted EPS at $1.46, down from $2.07 in the same quarter last year. Despite falling year on year, this print easily cleared analysts' estimates. Over the next 12 months, Wall Street expects Bristol-Myers Squibb's full-year EPS of $6.73 to shrink by 5%. Key Takeaways from Bristol-Myers Squibb's Q2 Results We were impressed by how significantly Bristol-Myers Squibb blew past analysts' EPS expectations this quarter. We were also excited its revenue outperformed Wall Street's estimates by a wide margin. On the other hand, full-year EPS guidance was lowered. Zooming out, we think this was a mixed print. The market seemed to be hoping for more, and the stock traded down 3.9% to $44.21 immediately following the results. Should you buy the stock or not? We think that the latest quarter is just one piece of the longer-term business quality puzzle. Quality, when combined with valuation, can help determine if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free. Sign in to access your portfolio
Yahoo
14 minutes ago
- Yahoo
Trump's Brazil Tariffs Upend Crop Prices From Coffee to Juice
(Bloomberg) -- US President Donald Trump's 50% tariff on goods from commodities powerhouse Brazil is upending crop markets, sending orange juice prices tumbling and coffee rising. The World's Data Center Capital Has Residents Surrounded An Abandoned Art-Deco Landmark in Buffalo Awaits Revival We Should All Be Biking Along the Beach Budapest's Most Historic Site Gets a Controversial Rebuild San Francisco in Talks With Vanderbilt for Downtown Campus Trump's executive order contained some meaningful exemptions including orange juice. Still, beef and coffee from the world's top exporter remain on the list of commodities that will be subject to import duties. Orange juice futures traded in New York plunged by the exchange maximum, while coffee surged as much as 3.5% on Thursday. Markets were already closed when the executive order was issued on Wednesday. 'The market reacted to news that coffee is not on the exemption list and, in theory, will be subject to tariffs,' said Fernando Maximiliano, an analyst at StoneX. 'There's still uncertainty about a possible exemption, but for now, it's a bullish sign for New York futures, and it means higher costs of coffee in the US.' The US accounts for about 40% of Brazil's orange juice exports and 16% of the nation's coffee shipments. While China is the biggest market for Brazil's beef, exports to the US had been on the rise as the American herd shrank to a 73-year low. Orange juice futures for September delivery fell by the exchange limit of 25 cents, dropping 8.8% to $2.6015 a pound on ICE Futures US. Arabica coffee jumped as much as 3.5% to $3.036 a pound before easing slightly to $2.971 a pound by 10:44 a.m. in New York. Even before Wednesday's announcement, the expectation of tariffs were already impacting coffee exports. US importers asked to delay shipments from Brazil, according to people familiar with deals that asked not to be identified discussing private negotiations. The move is already visible in the data. Brazil shipped just 2.4 million bags of coffee to all countries this month through July 29. That compares with 3.8 million bags for the whole month of July in 2024, according to data from industry group Cecafé. The nation is in the middle of its coffee harvest, so supplies are ample. Tariffs are also impacting the meat market, with industry group Abiec saying some plants have halted production of products usually shipped to the US. American beef imports from Brazil fell 23% this month through July 27, according to US Customs data compiled by IHS Markit. Brazilian authorities are still lobbying to gain more tariff exemptions. Cecafé and the National Coffee Association have said they are working toward that. Coffee is not produced in the continental US, and Commerce Secretary Howard Lutnick said in a CNBC interview on Tuesday that goods not produced in the US could be exempted from levies as trade deals are reached. 'Common sense has to prevail, and I think that will happen,' Judy Ganes, president at J. Ganes Consulting, said of the tariffs on coffee. 'But they're just not making it easy to get to that point, that's all. And so it creates a huge amount of angst.' --With assistance from Gerson Freitas Jr. and Mariana Durao. Russia Builds a New Web Around Kremlin's Handpicked Super App Burning Man Is Burning Through Cash Everyone Loves to Hate Wind Power. Scotland Found a Way to Make It Pay Off It's Not Just Tokyo and Kyoto: Tourists Descend on Rural Japan Cage-Free Eggs Are Booming in the US, Despite Cost and Trump's Efforts ©2025 Bloomberg L.P. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14 minutes ago
- Yahoo
Dream Finders Homes: Riding Out the Storm
Key Points Dream Finders reported solid growth in revenue and home closings, but higher expenses weighed on earnings. The company is following its playbook through the downturn, completing two acquisitions in the quarter. Dream Finders has ample resources to be opportunistic while housing is slow, but investors shouldn't expect a turnaround until macro forces realign and home buyers return to the market. 10 stocks we like better than Dream Finders Homes › Here's our initial take on Dream Finders Homes (NYSE: DFH) financial report. Key Metrics Metric Q2 2024 Q2 2025 Change vs. Expectations Revenue $1.06 billion $1.15 billion 9% Beat Earnings per share $0.81 $0.56 (31%) Missed Home closings 2,031 2,232 10% n/a Net new orders 1,712 1,938 13% n/a Dream Finders Remains On Course Despite Difficult Market Dream Finders grew revenue by 9% and home closings by 10% in what is a difficult housing environment, but higher homebuilding cost of sales and financial services expense ate into profitability. Homebuilding gross margin fell 250 basis points to 16.5%. Elevated interest rates, an uncertain economy, and pressures from soaring costs on home building supplies and labor have created what CEO Patrick Zalupski called "perhaps the most challenging environment in the past three years." Dream Finders continues to execute on its plan despite the downturn. In the quarter, the company closed deals for Alliant National Title Insurance Co. and Green River Builders, bringing its total to 10 acquisitions in the past six years. Alliant opens up new revenue sources, while Green River expands Dream Finders' presence in the fast-growing Atlanta area. The company also repurchased more than 700,000 shares for $16 million during the period. Immediate Market Reaction Investors knew going in that this was a tough housing market, and the results had little impact on sentiment. Dream Finders stock is down about 1% in early Thursday trading. What to Watch The big question facing homebuilders is when the housing market will turn. On Wednesday, the Federal Reserve held rates steady, and the odds of a September rate cut fell slightly, opening up the possibility of higher for longer on interest rates. Dream Finders ended the quarter with a backlog of 2,513 homes valued at $1.2 billion and reiterated its guidance for about 9,250 home closings in 2025. If the market remains weak, expect the company to continue to hunt for acquisition candidates in its core Sun Belt markets in anticipation of an eventual turnaround. The company cannot control the macro environment, and it is unlikely to see oversized growth until buyers return. But Dream Finders appears to be holding serve in a difficult climate, which is about the best investors can hope for for now. Helpful Resources Full earnings report Investor relations page Additional coverage Should you invest $1,000 in Dream Finders Homes right now? Before you buy stock in Dream Finders Homes, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Dream Finders Homes wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $638,629!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,098,838!* Now, it's worth noting Stock Advisor's total average return is 1,049% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Lou Whiteman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Dream Finders Homes. The Motley Fool has a disclosure policy. Dream Finders Homes: Riding Out the Storm was originally published by The Motley Fool Sign in to access your portfolio
